Clinical Trials

The Global Coalition for Adaptive Research (GCAR) in collaboration with Amgen and Eisai Co., Ltd., announced enrollment of the first patient in the immune modulation domain of REMAP-COVID, a sub-study of REMAP-CAP (A Randomized, Embedded, Multifactorial, Adaptive Platform trial...

AbbVie at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress show that significantly more atopic dermatitis patients treated with upadacitinib (15 mg or 30 mg; once daily) monotherapy achieved improvement in additional measures of skin clearance...

Baxter International Inc., a global leader in acute care, recognizes the findings of a prospective, multicenter, observational study on data from the OxirisNet Registry evaluating severely ill patients with COVID-19 in Italy treated with extracorporeal (outside the body) blood...

LabCorp , a leading global life sciences company that is focused on advancing health and guiding patient care decisions, announced new capabilities that will transform the clinical trial experience with the goal of streamlining the drug development process. This...

GSK announced that its Respiratory Syncytial Virus (RSV) candidate vaccines for maternal immunisation (GSK3888550A) and older adults (GSK3844766A) were well-tolerated and highly immunogenic in Phase I/II clinical studies. The data were presented virtually at the ID Week Congress. RSV is...

AstraZeneca’s long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside the US that are due to begin in the next weeks. The LAABs have been...

At Johnson & Johnson, there is no greater priority than the safety and well being of the people we serve every day around the world. We are committed to providing transparent updates throughout the clinical development process of our...